GSK (NYSE:GSK) Upgraded by Wall Street Zen to Buy Rating

GSK (NYSE:GSK) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other research firms have also issued reports on GSK. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price target for the company. Hsbc Global Res upgraded GSK to a “strong sell” rating in a research report on Monday, April 28th. Finally, Berenberg Bank restated a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $37.38.

GSK Trading Up 1.0%

GSK stock opened at $37.53 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.07. GSK has a 12-month low of $31.72 and a 12-month high of $44.67. The stock has a market cap of $76.62 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 1.64 and a beta of 0.51. The business’s 50-day moving average is $38.96 and its 200 day moving average is $37.70.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 EPS. On average, sell-side analysts anticipate that GSK will post 4.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC acquired a new position in GSK in the fourth quarter valued at approximately $528,000. Stamos Capital Partners L.P. lifted its holdings in GSK by 42.3% in the fourth quarter. Stamos Capital Partners L.P. now owns 294,820 shares of the pharmaceutical company’s stock valued at $9,971,000 after acquiring an additional 87,630 shares during the last quarter. First Hawaiian Bank lifted its holdings in GSK by 18.8% in the first quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company’s stock valued at $3,914,000 after acquiring an additional 15,987 shares during the last quarter. FMR LLC raised its position in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares during the period. Finally, Forum Financial Management LP lifted its stake in GSK by 167.9% during the fourth quarter. Forum Financial Management LP now owns 13,397 shares of the pharmaceutical company’s stock worth $453,000 after purchasing an additional 8,396 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.